Implementation of pooled saliva tests for universal screening of cCMV infection.

Autor: Merav L; School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel.; Department of Microbiology and Molecular Genetics, IMRIC, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Ofek Shlomai N; Department of Neonatology, Hadassah and Hebrew University Medical Center, Jerusalem, Israel.; Hebrew University Faculty of Medicine, Jerusalem, Israel., Oiknine-Djian E; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel.; Hebrew University Faculty of Medicine, Jerusalem, Israel.; Lautenberg Center for General and Tumor Immunology, Jerusalem, Israel., Caplan O; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Livneh A; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Sido T; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Peri A; Computing Department of Laboratories and Institutes, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Shtoyer A; Computing Department of Laboratories and Institutes, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Amir E; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Ben Meir K; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel.; Hebrew University Faculty of Medicine, Jerusalem, Israel.; Lautenberg Center for General and Tumor Immunology, Jerusalem, Israel., Daitch Y; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Rivkin M; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Kripper E; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Fogel I; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Horowitz H; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Greenberger S; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Cohen M; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel.; Hebrew University Faculty of Medicine, Jerusalem, Israel.; Lautenberg Center for General and Tumor Immunology, Jerusalem, Israel., Geal-Dor M; Speech and Hearing Center, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.; Department of Communication Disorders, Hadassah Academic College, Jerusalem, Israel., Gordon O; Hebrew University Faculty of Medicine, Jerusalem, Israel.; Pediatric Infectious Diseases, Pediatric Division, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Averbuch D; Hebrew University Faculty of Medicine, Jerusalem, Israel.; Pediatric Infectious Diseases, Pediatric Division, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Ergaz-Shaltiel Z; Department of Neonatology, Hadassah and Hebrew University Medical Center, Jerusalem, Israel.; Hebrew University Faculty of Medicine, Jerusalem, Israel., Eventov Friedman S; Department of Neonatology, Hadassah and Hebrew University Medical Center, Jerusalem, Israel.; Hebrew University Faculty of Medicine, Jerusalem, Israel., Wolf DG; Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel. dana.wolf@ekmd.huji.ac.il.; Hebrew University Faculty of Medicine, Jerusalem, Israel. dana.wolf@ekmd.huji.ac.il.; Lautenberg Center for General and Tumor Immunology, Jerusalem, Israel. dana.wolf@ekmd.huji.ac.il., Yassour M; School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel. moranya@mail.huji.ac.il.; Department of Microbiology and Molecular Genetics, IMRIC, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. moranya@mail.huji.ac.il.
Jazyk: angličtina
Zdroj: Nature medicine [Nat Med] 2024 Apr; Vol. 30 (4), pp. 1111-1117. Date of Electronic Publication: 2024 Mar 08.
DOI: 10.1038/s41591-024-02873-3
Abstrakt: Congenital cytomegalovirus (cCMV) is the most common intrauterine infection, leading to neurodevelopmental disabilities. Universal newborn infant screening of cCMV has been increasingly advocated. In the absence of a high-throughput screening test, which can identify all infected newborn infants, the development of an accurate and efficient testing strategy has remained an ongoing challenge. Here we assessed the implementation of pooled saliva polymerase chain reaction (PCR) tests for universal screening of cCMV, in two hospitals of Jerusalem from April 2022 through April 2023. During the 13-month study period, 15,805 infants (93.6% of all live newborn infants) were screened for cCMV using the pooled approach that has since become our routine screening method. The empirical efficiency of the pooling was six (number of tested newborn infants per test), thereby sparing 83% of the saliva tests. Only a minor 3.05 PCR cycle loss of sensitivity was observed for the pooled testing, in accordance with the theoretical prediction for an eight-sample pool. cCMV was identified in 54 newborn infants, with a birth prevalence of 3.4 per 1,000; 55.6% of infants identified with cCMV were asymptomatic at birth and would not have been otherwise targeted for screening. The study demonstrates the wide feasibility and benefits of pooled saliva testing as an efficient, cost-sparing and sensitive approach for universal screening of cCMV.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: